Abstract:Inhibition of tumor angiogenesis is an anticancer strategy in which neovasculature is targeted because tumor progression relies on neovascularization. The soluble, truncated form of vascular endothelial growth factor receptor-2 (VEGFR-2), sFLK-1, is a well-known inhibitor of endothelial cells. This kind of soluble receptor retains its high-affinity binding to VEGF, but cannot work with the receptor tyrosine transphosphorylation and activation of downstream signal transduction to induce endothelial proliferation due to the lack of the tyrosine kinase domain. Therefore, we tried to use this sFLK-1 as an inhibitor for malignant tumor gene therapy. In this study we transferred a soluble VEGFR-2 (sFLK-1) from embryo mouse liver by RT-PCR to PA317 cells through retroviral vector (pLXSN) and obtained stable expression. NIH3T3 cells were used for measuring the virus titer. The virus titer in this experiment was 2 x 10(7) CFU/ml. After 7 days of preparing subcutaneous tumor models bearing S180, MCF-7, and B16 cells in mice, respectively, 2 x 10(7) PFU of recombinant retroviruses were injected locally into the tumors the treatment groups. After treatment, the tumor size and weight were significantly smaller than that of control (p < 0.05). After autopsy, the metastasic focus numbers in the treatment groups were also less than control groups. We also measured VEGFR-2 expression in tumor tissues by Western blot to check if sFLK-1 had been integrated into the cells of tumor tissues. Expression in the treatment groups was significantly greater than that of control groups (p < 0.001). Microvessel. density (MVD) and proliferative cell nuclear antigen (PCNA) were investigated to determine whether the Re-sFLK-1 fragment had the ability to inhibit tumor angiogenesis and proliferation in mice bearing S180 and MCF-7 cells. The results showed that MVD and PCNA in the treatment groups were lower than in control groups. There were significant difference between treatment groups and control groups (p < 0.0001). The results indicated that retroviral-mediated sFLK-1 gene therapy in animal tumor models has significant therapeutic effect.

VEGF receptor-2-specific signaling mediated by VEGF-E induces hemangioma-like lesions in normal and in malignant tissue

Vegf Upregulates Vegf Receptor-2 on Human Outer Root Sheath Cells and Stimulates Proliferation Through Erk Pathway

Direct Evidence for Endothelial Vascular Endothelial Growth Factor Receptor-1 Function in Nitric Oxide-Mediated Angiogenesis

Transgenic Rabbits with Increased VEGF Expression Develop Hemangiomas in the Liver: a New Model for Kasabach–Merritt Syndrome

Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1)

Vegf Induces Proliferation of Human Hair Follicle Dermal Papilla Cells Through Vegfr-2-Mediated Activation of Erk

Distinct Vascular Endothelial Growth Factor Signals for Lymphatic Vessel Enlargement and Sprouting.

Ultrastructural Localization of the Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Receptor-2 (FLK-1, KDR) in Normal Mouse Kidney and in the Hyperpermeable Vessels Induced by VPF/VEGF-expressing Tumors and Adenoviral Vectors

Ectodomain shedding of VEGF183, a novel isoform of vascular endothelial growth factor, promotes its mitogenic activity in vitro

Establishment of Rat Heomangioma Model by Implantation of Vascular Endothelial Growth Factor Gene

A Critical Role of VEGFR2 in Lymphatic Tumor Metastasis

Tumor-derived Vascular Endothelial Growth Factor (Vegf)-a Facilitates Tumor Metastasis Through the VEGF-VEGFR1 Signaling Pathway.

VEGF/Flk1 Signaling Cascade Transactivates Etv2 Gene Expression.

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

The Expression and angiogenesis Effect of VEGF gene

Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain.

Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR

Gene Therapeutic Exploration: Retrovirus-Mediated Soluble Vascular Endothelial Growth Factor Receptor-2 (Sflk-1) Inhibits the Tumorigenicity of S180, Mcf-7, and B16 Cells in Vivo

Requisite endothelial reactivation and effective siRNA nanoparticle targeting of Etv2/Er71 in tumor angiogenesis

In Vivo Inhibition of Tumor Angiogenesis by A Soluble Vegfr-2 Fragment

Isoform-specific Expression of VEGF-B in Normal Tissues and Tumors